The Alzheimer’s Drug Pipeline report delivers a comprehensive look at late-stage Alzheimer’s drugs in Phase II and III clinical trials and provides a realistic estimate of when these drugs could potentially reach the market in the next five to 10 years. This analysis was constructed through extensive research, including examination of company reports, public databases, media coverage, presentations from medical conferences, interviews with company executives about publicly available information, and SEC filings.

FOCUS AREA

The Alzheimer’s Drug Pipeline report delivers a comprehensive look at late-stage Alzheimer’s drugs in Phase II and III clinical trials and provides a realistic estimate of when these drugs could potentially reach the market in the next five to 10 years. This analysis was constructed through extensive research, including examination of company reports, public databases, media coverage, presentations from medical conferences, interviews with company executives about publicly available information, and SEC filings.

TOPLINE INSIGHTS

This year, three new Mechanisms of Action – i.e., pathways to attack Alzheimer’s disease – have emerged in the pipeline: stem cell, antimicrobial, and endocrine. This speaks to a continuing diversification of the pipeline and demonstrates the broad range of ideas being considered to fight the disease.

Phase II drugs targeting amyloid – historically one of the most popular targets of pharmacological attack in fighting Alzheimer’s – have increased 30% since 2017, indicating maintained interest in this pathway. That number has dropped nearly 50% in Phase III, however, possibly due to an ultimately low success rate.

The future of a pharmacological cure for Alzheimer’s lies in a “cocktail” approach – a combination of pharmacological treatments that target a variety of Mechanisms of Action working together to treat and cure the disease.